Lensar reports Q4 EPS (12c) vs. ($1.61) last year

Reports Q4 revenue $16.03M vs. $16.73M last year. “While the recent transaction-related news was unexpected, we have quickly pivoted and are moving forward independently with a renewed commitment to advancing robotic laser cataract surgery through our industry-leading ALLY Robotic Laser Cataract System. Our objective is not only to expand our share of the laser-assisted cataract surgery market, but to expand the robotic laser cataract market itself, and continue to demonstrate we are well equipped to do so,” said CEO Nick Curtis. “We closed 2025 with continued momentum in ALLY adoption and utilization, reinforcing the durability of our recurring revenue model, with 79% of revenue for both the fourth quarter and the full year coming from recurring sources. During Q4, we expanded the ALLY installed base to approximately 200 systems, representing a 48% increase over the end of 2024, while worldwide volume increased 22% in 2025 compared to 2024. Procedure growth, both in the U.S. and abroad, remained robust and reflects increasing utilization across our growing installed base, providing clear evidence of the compelling value surgeons see in our technology and a clear path for LENSAR (LNSR) to continue growing its recurring revenue base and its overall business.”